Prävention des Typ-2-Diabetes mellitus: Bewährtes und Neues

Schlüsselwörter

Diabetes - Prävention - Betazellen

Key words

Diabetes - prevention - beta-cells

Literatur

• 1 Leben in Deutschland - Haushalte, Familien und Gesundheit - Mikrozensus 2005. Wiesbaden: Statistisches Bundesamt
• 2 Buchanan T A, Xiang A H, Peters R K. et al . Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.  Diabetes. 2002;  51 2796-2803
• 3 Butler A E, Jang J, Gurlo T, Carty M D, Soeller W C, Butler P C. Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes.  Diabetes. 2004;  53 1509-1516
• 4 Butler A E, Janson J, Bonner-Weir S, Ritzel R, Rizza R A, Butler P C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.  Diabetes. 2003;  52 102-110
• 5 Butler P C, Ritzel R A, Butler A E, Rizza R A. Islet Turnover in Lean and Obese Humans (Abstract).  Diabetes. 2004;  53 (Suppl 2) P1479
• 6 Chen J, Couto F M, Minn A H, Shalev A. Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein.  Biochem Biophys Res Commun. 2006;  346 1067-1074
• 7 Chiasson J L, Josse R G, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.  Lancet. 2002;  359 2072-2077
• 8 Diabetes Prevention Program Research G . Within-Trial Cost-Effectiveness of Lifestyle Intervention or Metformin for the Primary Prevention of Type 2 Diabetes.  Diabetes Care. 2003;  26 2518-2523
• 9 Drucker D J, Nauck M A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.  Lancet. 2006;  368 1696-1705
• 10 Farilla L, Bulotta A, Hirshberg B. et al . Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.  Endocrinology. 2003;  144 5149-5158
• 11 Florez J C, Jablonski K A, Bayley N. et al . TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program.  N Engl J Med. 2006;  355 241-250
• 12 Gelfand E V, Cannon C P. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.  J Am Coll Cardiol. 2006;  47 1919-1926
• 13 Gerich J E. Postprandial hyperglycemia and cardiovascular disease.  Endocr Pract. 2006;  12 (Suppl 1) 47-51
• 14 Gerstein H C, Yusuf S, Bosch J. et al . Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.  Lancet. 2006;  368 1096-1105
• 15 Grey A, Bolland M, Gamble G. et al . The Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial.  J Clin Endocrinol Metab. 2007;  92 1305-1310
• 16 Hauner H, Landgraf R, Schulze J, Spranger J, Standl E. Prevention of type 2 diabetes mellitus. Position paper of the National Action Forum for Diabetes Mellitus.  Dtsch Med Wochenschr. 2005;  130 1053-1054
• 17 Kahn S E, Haffner S M, Heise M A. et al . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.  N Engl J Med. 2006;  355 2427-2443
• 18 Knowler W C, Barrett-Connor E, Fowler S E. et al . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 393-403
• 19 Kubaszek A, Pihlajamaki J, Komarovski V. et al . Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study.  Diabetes. 2003;  52 1872-1876
• 20 Lin C Y, Gurlo T, Haataja L, Hsueh W A, Butler P C. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3’-kinase-dependent pathway.  J Clin Endocrinol Metab. 2005;  90 6678-6686
• 21 Lindstrom J, Ilanne-Parikka P, Peltonen M. et al . Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.  Lancet. 2006;  368 1673-1679
• 22 Ozcan U, Cao Q, Yilmaz E. et al . Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes.  Science. 2004;  306 457-461
• 23 Pan X R, Li G W, Hu Y H. et al . Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and Diabetes Study.  Diabetes Care. 1997;  20 537-544
• 24 Pfeiffer A F. Präventionsstrategien für Prädiabetes.  Dtsch Med Wochenschr. 2005;  130 1059-1060
• 25 Pi-Sunyer F X, Aronne L J, Heshmati H M, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.  Jama. 2006;  295 761-775
• 26 Pick A, Clark J, Kubstrup C. et al . Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat.  Diabetes. 1998;  47 358-364
• 27 Pospisilik J A, Martin J, Doty T. et al . Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.  Diabetes. 2003;  52 741-750
• 28 Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar A D, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).  Diabetologia. 2006;  49 289-297
• 29 Ritzel R A, Butler A E, Rizza R A, Veldhuis J D, Butler P C. Relationship between beta-cell mass and fasting blood glucose concentration in humans.  Diabetes Care. 2006;  29 717-718
• 30 Ritzel R A, Butler P C. Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosis.  Diabetes. 2003;  52 1701-1708
• 31 Scheen A J, Finer N, Hollander P, Jensen M D, Van Gaal L F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.  The Lancet. 2006;  368 1660
• 32 Schwarz P. Gezielte Diabetesprävention in Risikogruppen: Pro.  Dtsch Med Wochenschr. 2005;  130 1103
• 33 Schwarz P E, Gruhl U, Schuppenies A, Schulze J, Bornstein S R. [Prevention of diabetes mellitus: the future of German diabetology].  Hamostaseologie. 2007;  27 13-21
• 34 Schwarz P E, Schuppenies A, Gruhl U. et al . Prevention of type 2 diabetes in Germany. Ideas, evidence, implementation.  Med Klin (Munich). 2006;  101 730-736
• 35 Sladek R, Rocheleau G, Rung J. et al . A genome-wide association study identifies novel risk loci for type 2 diabetes.  Nature. 2007;  445 881-885
• 36 The DTI . Effect of Ramipril on the Incidence of Diabetes.  N Engl J Med. 2006;  355 1551-1562
• 37 Tuomilehto J, Lindstrom J, Eriksson J G. et al . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med. 2001;  344 1343-1350
• 38 Van Gaal L F, Rissanen A M, Scheen A J, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.  Lancet. 2005;  365 1389-1397
• 39 Woerle H J, Pimenta W P, Meyer C. et al . Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c values.  Arch Intern Med. 2004;  164 1627-1632
• 40 Yusuf S, Gerstein H, Hoogwerf B. et al . Ramipril and the development of diabetes.  Jama. 2001;  286 1882-1885
• 41 Zeender E, Maedler K, Bosco D, Berney T, Donath M Y, Halban P A. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta.  J Clin Endocrinol Metab. 2004;  89 5059-5066